← Leaderboards
Ferdinandos Skoulidis
University Of Tx Md Anderson Can Ctr
$4,461,361
Attributed
$5,357,422
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,357,422 · 4
By mechanism
R01$5,357,422 · 4
Top collaborators
- Seyed Javad Mirhassani Moghaddam2 shared
- David John Tweardy2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Seyed Javad Mirhassani Moghaddam$4,738,281
- Jianjun Gao$3,992,332
- Don Lynn Gibbons$4,258,623
- Courtney Dinardo$2,316,391
- Kapil N. Bhalla$16,921,043
Others in their field
Other Emerging Leaders on “Cessation Of Life”
- Xinhua Li · Nano Terra, Inc.$32,520,955
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Abraham Aizer Brody · New York University School Of Medicine$21,799,826
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$20,810,724
- Jeffrey Reich · Sparian Biosciences, Inc.$20,633,040
- Beth Baseler · Leidos Biomedical Research, Inc.$18,109,529
Research focus
Cessation Of LifePathway InteractionsImmuneMouse ModelMutantKras2 GeneTumorSamplingResponseOncogenicNon-Small-Cell Lung CarcinomaImmunocompetentNeoplastic CellMutationAnimal ModelDna Sequence AlterationSpecimenClinically SignificantClinical EfficacyCellsPre-Clinical ModelMolecularPropertyShapes
Grant awards (13)
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor$671,795
R01 · FY2025 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer$370,575
R01 · FY2025 · CA · contact PI
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer$370,575
R01 · FY2025 · CA · contact PI
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.$370,575
R01 · FY2025 · CA · contact PI
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor$672,297
R01 · FY2024 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer$352,047
R01 · FY2024 · CA · contact PI
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.$352,047
R01 · FY2024 · CA · contact PI
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer$352,047
R01 · FY2024 · CA · contact PI
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer$370,575
R01 · FY2023 · CA · contact PI
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.$370,575
R01 · FY2023 · CA · contact PI
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer$363,164
R01 · FY2023 · CA · contact PI
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer$370,575
R01 · FY2022 · CA · contact PI
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer$370,575
R01 · FY2021 · CA · contact PI